InterVenn Biosciences Announces that Nobel Laureate James P. Allison, PhD, has Joined the Company’s Board of Advisors

InterVenn Biosciences today announced that Nobel Prize recipient, James P. Allison, has joined the company’s Board of Advisors, effective March 9, 2021. Dr. Allison joins the InterVenn Board of Advisors with over 45 years of experience in Immunology and cancer research.

James Allison is the Regental Professor and Chair of the Department of Immunology, the Olga Keith Wiess Distinguished University Chair for Cancer Research, Director of the Parker Institute for Cancer Research, and the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. Dr. Padmanee Sharma, MD, PhD, Dr. Allison’s close collaborator at MD Anderson Cancer Center, is also joining InterVenn’s Board of Advisors.

Dr. Allison was awarded the 2018 Nobel Prize in Physiology or Medicine for discovery of an effective new way to treat cancer by leveraging the body’s immune system to attack the tumor. Dr. Allison is the first MD Anderson scientist to receive the world’s most prestigious award for outstanding discoveries in the fields of life science and medicine.

Dr. Allison is a pioneer in the immuno-oncology research field. He established a new principle for cancer therapy involving the activation of the immune system to fight cancer cells. His studies of T-cell receptor structure, and his demonstration that blockade of a T-cell inhibiting protein, CTLA-4, allows the immune system to effectively fight cancer opened the way to the first checkpoint-inhibitor therapy, and its approval by FDA. The concept of enabling the immune system to actively interfere with malignant cells has since become the backbone of immuno-oncology therapies, with large numbers of powerful new drugs already available to patients today or in clinical development.

“We are extremely grateful to welcome Jim to our board,” said Aldo Carrascoso, Co-Founder and Chief Executive Officer of InterVenn Biosciences. “Jim’s leadership in the field of immunotherapy brings outstanding value to InterVenn, and we look forward to his expertise and guidance this year and in the years to come.”

About InterVenn Biosciences

InterVenn Biosciences utilizes a proprietary high-throughput glycoproteomic interrogation platform using artificial intelligence and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression. For more information about InterVenn Biosciences, please visit the company’s website.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005369/en/